Anti-MUC1 CAR-T cell and its preparation method and application
A technology of cells and lymphocytes, applied in the field of gene-modified cells and tumor treatment, to achieve the effect of high-efficiency tumor-killing activity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0043] Preparation of Anti MUC1 CAR-T cells of the present invention
[0044] 1. Construction of lentiviral expression vector
[0045] Through conventional genetic engineering methods, the SCFV-IgD-CD28-OX40-CD3ζ fusion protein gene sequence was synthesized, and the SCFV-IgD-CD28-OX40-CD3ζ fusion protein gene sequence was cloned into a lentiviral expression vector to obtain SCFV-IgD-CD28 –OX40–CD3ζ lentiviral expression vector pGreen puro-CAR. Wherein, each sequence of the SCFV-IgD-CD28-OX40-CD3ζ fusion protein is as described above.
[0046] 2. Lentiviral packaging
[0047] 1) Culture 293T cells in 1640 medium with a mass fraction of 10 wt% fetal bovine serum (fetal bovine serum, FBS for short);
[0048] 2) 293T cells were treated with 3x 10 5 / cm 2 Transfer the density to a culture dish with a diameter of 15cm and cultivate it for 20h to ensure that the cell confluence is 80-90% during transfection;
[0049] Replace the medium with serum-free 1640 medium and set aside;...
Embodiment 2
[0063] The in vitro anti-tumor effect of the Anti MUC1 CAR-T cells prepared in Example 1 was evaluated, including the following steps:
[0064] With breast cancer cell line MCF-7 and pancreatic cancer cell line BxPC-3 stably expressing MUC1 as target cells, T cells infected with lentiviral vector pGreen puro-CAR (i.e., Anti MUC1 CAR-T cells prepared in Example 1 cells) and uninfected T cells to make effector cells, target cells according to the density of 1x 10 5 cells / ml inoculated in 96-well plate, 100 μl per well, added effector cells to target cells according to 5:1, 10:1, 20:1 effect-to-target ratio, placed in 5% CO 2 , cultured in a 37°C incubator for 4 hours, using WST-1 to detect cell viability, and calculate the killing efficiency.
[0065] figure 2 It is a schematic diagram of the killing effect of Anti MUC1 CAR-T cells and uninfected T cells on the target cell MCF-7 (breast cancer) according to the embodiment of the present invention; image 3 It is a schematic ...
Embodiment 3
[0068] The anti-tumor effect of the Anti MUC1 CAR-T cells prepared in Example 1 was evaluated in vivo, including the following steps:
[0069] Take 15 6-week-old female nude mice and inject 5x 10 subcutaneously in the right armpit 6 MCF-7 (breast cancer) cells, when the tumor grows to 60mm 3 Size, tumor model was randomly divided into 3 groups: control group, Anti MUC1 CAR-T cell group, T cell group; control group was injected with normal saline 200ul / time, twice a week; Anti MUC1 CAR-T cell group was injected with tail vein Anti MUC1 CAR-T cells 1×10 7 T cells / time, 2 times a week; T cells in the T cell group were injected into the tail vein 1×10 7 Each time, twice a week; the survival status of the mice within 100 days was counted, and the survival rate curve was made. Figure 4 It is a schematic diagram of the survival period of mice treated with breast cancer (MCF-7) xenografted tumor model mice by Anti MUC1 CAR-T cells of the embodiment of the present invention, contro...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com